Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer--is it justified?
Murphy
M
M
Brown
A E
AE
Sepkowitz
K A
KA
Bernard
E M
EM
Kiehn
T E
TE
Armstrong
D
D
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D004358:Drug Therapy / Q000379:methods / Q000523:psychology*; D004754:Enterobacter / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009026:Mortality; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D016019:Survival Analysis
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002939:Ciprofloxacin